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In accordance with the prominent role of orexins in the maintenance of wakefulness
via activation of orexin-1 (OX1R) and orexin-2 (OX2R) receptors, various dual OX1/2R
antagonists have been shown to promote sleep in animals and humans. While selective
blockade of OX2R seems to be sufficient to initiate and prolong sleep, the beneficial
effect of additional inhibition of OX1R remains controversial. The relative contribution of
OX1R and OX2R to the sleep effects induced by a dual OX1/2R antagonist was further
investigated in the rat, and specifically on rapid eye movement (REM) sleep since a
deficiency of the orexin system is associated with narcolepsy/cataplexy based on clinical
and pre-clinical data. As expected, the dual OX1/2R antagonist SB-649868 was effective
in promoting non-REM (NREM) and REM sleep following oral dosing (10 and 30mg/kg)
at the onset of the dark phase. However, a disruption of REM sleep was evidenced by a
more pronounced reduction in the onset of REM as compared to NREM sleep, a marked
enhancement of the REM/total sleep ratio, and the occurrence of a few episodes of direct
wake to REM sleep transitions (REM intrusion). When administered subcutaneously, the
OX2R antagonist JNJ-10397049 (10mg/kg) increased NREM duration whereas the OX1R
antagonist GSK-1059865 (10mg/kg) did not alter sleep. REM sleep was not affected
either by OX2R or OX1R blockade alone, but administration of the OX1R antagonist in
combination with the OX2R antagonist induced a significant reduction in REM sleep
latency and an increase in REM sleep duration at the expense of the time spent in NREM
sleep. These results indicate that additional blockade of OX1R to OX2R antagonism elicits
a dysregulation of REM sleep by shifting the balance in favor of REM sleep at the expense
of NREM sleep that may increase the risk of adverse events. Translation of this hypothesis
remains to be tested in the clinic.
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INTRODUCTION
The orexin neuropeptides produced by lateral hypothalamic neu-
rons play a critical role in the maintenance of wakefulness by
activating two distinct receptors, the orexin-1 (OX1R) and the
orexin-2 (OX2R) receptor that are widely distributed throughout
the brain (De Lecea et al., 1998; Peyron et al., 1998; Sakurai et al.,
1998). The orexin system is believed to stabilize the wake-sleep
flip-flop switch in wake-active structures consisting of histamin-
ergic, monoaminergic, and cholinergic neurons (Saper et al.,
2001), and also to regulate the onset of rapid eye movement
(REM) sleep and associated muscular atonia in the brainstem (Lu
et al., 2006). In accordance with the prominent function of orex-
ins in sustaining wakefulness, pharmacological blockade of both
OX1R and OX2R (OX1/2R) has been shown to promote sleep
in various species, and the dual OX1/2R antagonists almorex-
ant, SB-649868 and suvorexant have been clinically validated for
the treatment of insomnia (Winrow and Renger, 2014). Further
investigations conducted in rodent models on the specific role of
OX1R and OX2R in sleep modulation indicate that while selective
blockade of OX2R seems to be sufficient to initiate and prolong
sleep (Dugovic et al., 2009; Mang et al., 2012), the beneficial effect
of additional inhibition of OX1R remains controversial (Morairty
et al., 2012).
OX1R and OX2R are differentially distributed in structures
regulating sleep and wake, with OX1R exclusively expressed in
the locus coeruleus, OX2R selectively expressed in the tubero-
mammillary nucleus, and both receptors co-expressed in the
dorsal raphe (Sakurai et al., 1998; Marcus et al., 2001), suggest-
ing a distinct function between the two orexin receptors. It has
been proposed that OX2R signaling is essential for the promo-
tion of wakefulness and the transition to non-REM (NREM)
sleep and that both OX1R and OX2R contribute to REM sleep
suppression (Willie et al., 2003; Mieda et al., 2011; Mochizuki
et al., 2011). Loss or disruption of orexin signaling in human
and animal narcolepsy is associated with reduced activity of the
wake-promoting system, frequent transitions into NREM sleep,
and abnormal intrusions of REM sleep into wake accompanied
by loss of muscular tone and cataplexy (Nishino, 2007). During
their dark/active phase, mice lacking the orexin peptide as well
as mice lacking both OX1R and OX2R spend more time in REM
sleep, whereas NREM sleep duration is unaffected as compared
to their corresponding wild type (Willie et al., 2003; Sakurai,
www.frontiersin.org February 2014 | Volume 8 | Article 28 | 1
Dugovic et al. Orexin-1 receptor blockade dysregulates REM
2007; Mang et al., 2012). Previous work in our lab has indicated
that simultaneous blockade of OX1R attenuates the NREM sleep-
promoting effects evoked by a selective OX2R antagonist but not
the REM sleep promotion when assessed for a 2-h period during
the light/rest phase in rats (Dugovic et al., 2009).
In the present study, we further explored the respective con-
tributions of OX1R and OX2R on the sleep-promoting effects
elicited by pharmacological blockade of both receptors, and
specifically on REM sleep since a deficiency of the orexin sys-
tem is associated with narcolepsy/cataplexy based on clinical
and pre-clinical data. In order to detect possible events reminis-
cent of narcoleptic-like symptoms such as REM intrusion into
wakefulness, the investigation was conducted during the active
phase of the animals. The effects of the dual OX1/2R antago-
nist SB-649868 (Di Fabio et al., 2011) were compared to those
obtained by co-administration of the selective OX1R antagonist
GSK-1059865 (Gozzi et al., 2011) and the selective OX2R antag-
onist JNJ-10397049 (McAtee et al., 2004) during the dark phase
in rats.
MATERIALS AND METHODS
ANIMALS
Studies were performed in male Sprague–Dawley rats (Harlan
Laboratories, weighing 350–450 g). Animals were approximately
4 months of age at the start of the study and were housed individ-
ually in cages under controlled conditions with lights on at 6 AM
(12:12 light/dark schedule) while temperature was maintained at
22 ± 2◦C. During the course of the study, animals had ad libitum
access to food and water. All procedures detailed in this investiga-
tion were implemented in accordance with policies established by
the Guide for the Care and Use of Laboratory Animals as adopted
by the United States National Institutes of Health.
DRUGS AND EXPERIMENTAL DESIGN
SB-649868 is a dual OX1/2R antagonist with similar potency at
both receptor subtypes (pKi OX1R = 9.5, pKi OX2R = 9.4)
and the doses tested were selected in accordance with the phar-
macokinetic profile and hypnotic activity in rats described for
this compound (Di Fabio et al., 2011). GSK-1059865 is a selec-
tive OX1R antagonist that shows a 80 fold higher selectivity vs.
OX2R (Gozzi et al., 2011). We confirmed the high selectivity
of GSK-1059865 (pKi OX1R = 8.3, pKi OX2R = 6.4; unpub-
lished data). GSK-1059865 (10mg/kg) achieved about 90%OX1R
occupancy 15min after subcutaneous (sc) administration which
was maintained for 4 h, as determined by ex vivo autoradiogra-
phy in the rat brain (manuscript in preparation). JNJ-10397049
is a selective OX2R antagonist (pKi OX2R = 8.2, pKi OX1R
= 5.7). JNJ-10397049 (30mg/kg) achieved about 80% of OX2R
occupancy 15min after sc administration which was maintained
for 6 h, as determined by ex vivo autoradiography in rat cortex
(Dugovic et al., 2009). SB-649868, JNJ-10397049, and GSK-
1059865 were synthesized at Janssen Research & Development,
L.L.C. SB-649868 (10 and 30mg/kg) was dosed orally as a
suspension of 0.5% methylcellulose in a volume of 1ml/kg.
JNJ-10397049 (10mg/kg) and GSK-1059865 (10mg/kg) were
administered via the subcutaneous (sc) route. GSK-1059865
and JNJ-10397049 were formulated in 5% pharmasolve, 20%
solutol, 75% hydroxypropyl-β-cyclodextrin (20% w/v), and were
injected as a free base form of the compound in a volume
of 1ml/kg.
The dose-response experiment with SB-649868 was carried
out in a group of animals (n = 8) assigned to three treatment
conditions (vehicle, n = 8; 10mg/kg, n = 7; 30mg/kg, n = 7).
The experiment with the simultaneous coadministration of GSK-
1059865 and JNJ-10397049 was carried out on a separate group
of rats (n = 7) assigned to four treatment conditions (vehicle +
vehicle, GSK-1059865 + vehicle, vehicle + JNJ-10397049, and
GSK-1059865 + JNJ-10397049). Both experiments were con-
ducted in a randomized cross-over design and a minimum of 3
days washout period were allowed between two treatments.
SLEEP RECORDING AND ANALYSIS
Animals were implanted with telemetric devices for polysomno-
graphic recording of sleep-wake patterns as previously described
(Dugovic et al., 2009). To determine states of vigilance,
polysomnographic waveforms were acquired from two stainless
steel screw electrodes that were implanted under isofluorane anes-
thesia in the frontal and parietal cortex for the electroencephalo-
gram (EEG) and in dorsal nuchal muscles for the electromyogram
(EMG). Electrodes were coupled to a sterile two-channel telemet-
ric device (PhysioTel F40-EET; Data Sciences International, St.
Paul, MN) that had been implanted in the intraperitoneal cavity
in order to acquire measurements of body temperature and loco-
motor activity. After a 2-week period of recovery from surgery,
animals were transferred to their designated housing/procedure
room to allow for adaptation to the recording chamber and
environment.
EEG and EMG signals were recorded for up to 12 h post-
drug administration and were digitized at a sampling rate of
100Hz on an IBM PC-compatible computer using Dataquest
A.R.T software (Data Sciences International). Using the computer
software program SleepSign (Kissei Comtec, Nagano, Japan),
consecutive EEG/EMG recordings were divided into individual
10 sepochs that were then visually assigned vigilance states based
upon conventional criteria for wake, NREM sleep and REM
sleep as described previously. EEG activity within specific vigi-
lance states was determined by power spectral analysis using the
Fast Fourier Transform performed within a frequency range of
1–30Hz. Values for power spectra were divided into four fre-
quency bands: delta (1–4Hz), theta (4–10Hz), sigma (10–15Hz),
and beta (15–30Hz).
Analysis of sleep-wake parameters included latency (onset) to
NREM sleep (defined as the time interval to the first six consec-
utive NREM epochs) and REM sleep (the first two consecutive
REM epochs post-injection), the duration of wake, NREM and
REM sleep and bout analysis (number and duration) for each
vigilance state. In addition, episodes of direct wake to REM
sleep (DREM) transitions were assessed. A DREM transition was
defined as an abrupt episode of nuchal atonia and EEG domi-
nance of theta activity lasting at least a 10 s epoch with at least
six consecutive 10 s epochs of wake (60 s) preceding the episode.
As a comparison, a criteria of at least 40 s of wakefulness preced-
ing an episode of cataplexy has been defined in mouse models of
narcolepsy (Scammell et al., 2009).
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Results were averaged and expressed as mean ±s.e.m. in
defined time intervals. To determine whether differences were sig-
nificant at a given interval, either a One-Way analysis of variance
(ANOVA) with Newman–Keuls or Dunnett’s multiple compar-
ison post-hoc analysis, or Two-Way repeated measures ANOVA
followed by a Bonferroni post-hoc test was performed.
RESULTS
DIFFERENTIAL NREM AND REM SLEEP-PROMOTING EFFECTS OF THE
DUAL OX1/2R ANTAGONIST SB-649868
When administered at the onset of the dark phase, the dual
OX1/2R antagonist SB-649868 significantly reduced the laten-
cies for NREM and REM sleep, and significantly prolonged the
time spent in each of these sleep states at the two doses tested,
10 and 30mg/kg (Figure 1). However, REM sleep was predom-
inantly affected relative to NREM sleep in regard to its onset
and total duration. The latency for NREM sleep was reduced
by half (Figure 1A), whereas the latency for REM sleep was
FIGURE 1 | Sleep-promoting effects of the dual OX1/2R antagonist
SB-649868 in rats. Latency to NREM (A) and REM (B) sleep and duration
of NREM (C,D) and REM (E,F) sleep during the 12-h dark phase after oral
dosing (10 and 30mg/kg) are expressed in minutes and are represented as
means ± s.e.m. (n = 7–8 animals per condition). ∗P < 0.05, ∗∗P < 0.01,
and ∗∗∗P < 0.001 vs. vehicle, based on One-Way ANOVA followed by
Dunnett’s multiple comparison post-hoc test (A) [F(2, 19) = 70.60,
p < 0.001], (B) [F(2, 19) = 14.05, p < 0.001], (D) [F(2, 19) = 9.57, p = 0.001],
and (F) [F(2, 19) = 127.50, p < 0.001] or two-way ANOVA (interaction
Time × Treatment) followed by Bonferroni post-hoc test
(C) [F(10, 144) = 2.45, p = 0.011] and (E) [F(10, 114) = 8.07, p < 0.001].
diminished by about 75% (Figure 1B) as compared to the vehi-
cle condition, leading to an almost similar onset for both states.
Similarly, the time course of the effects on REM sleep differed
from the effects on NREM sleep. The increase in NREM sleep
duration occurred mostly during the first 2 h after the treat-
ment (Figure 1C), whereas the increase in REM duration lasted
for 8 h at the 10mg/kg dose and for the entire 12-h dark phase
following the dose of 30mg/kg (Figure 1E). In the total 12-h
period, the increase in NREM sleep duration was significant at
the high dose only (Figure 1D) whereas REM sleep was signifi-
cantly increased at both doses tested (Figure 1F). Further analysis
of the sleep macrostructure showed that while the numbers of
both NREM and REM bouts were dose-dependently enhanced,
the NREM bout duration was reduced but the REM bout dura-
tion was prolonged (Table 1). Therefore, the net increase in the
time spent in NREM sleep might be attenuated due to a decrease
in NREM sleep continuity in spite of the increase in its frequency.
In contrast, both the frequency and continuity in REM sleep were
increased, leading to a larger increment in the total REM sleep
duration. In addition, a careful visual analysis of the EEG and
EMG signals revealed scarce episodes of direct transitions from
wake to REM sleep (DREM). DREM episodes occurred in 3 out
of 7 rats treated with the highest dose of 30mg/kg, and in one
animal which received the dose of 10mg/kg as illustrated in the
hypnogram and the EEG/EMG traces corresponding to this event
(Figure 2). Power spectral analysis indicates that the averaged
EEG relative power in the theta frequency band (4–10Hz) dur-
ing this DREM episode (45% of the total power) was comparable
to the relative theta power during a normal episode of REM sleep
(49%) shown in Figure 2 for this animal. The averaged EEG theta
activity contributed to 26% of the total power during the 40 s
wake episode preceding DREM and to 31% during the 50 s wake
episode following DREM, indicating a distinct range of power
density values compared to the theta activity during DREM.
DISINHIBITION OF REM SLEEP BY ADDITIONAL PHARMACOLOGICAL
BLOCKADE OF OX1R TO OX2R ANTAGONISM
To further investigate the differential actions of the dual OX1/2R
antagonist on NREM and REM sleep, rats were adminis-
tered either with the selective OX1R antagonist GSK-1059865
Table 1 | NREM and REM bout analysis after oral administration of
the dual OX1/2R antagonist SB-649868 in rats.
NREM bout NREM bout REM bout REM bout
number duration (min) number duration (min)
Vehicle 154.4± 4.8 1.57± 0.04 31.9± 2.5 1.32± 0.07
10mg/kg 211.1± 9.1*** 1.22± 0.07*** 46.7± 2.8** 1.85± 0.09**
30mg/kg 248.4± 7.6*** 1.15± 0.04*** 52.0± 3.2*** 2.02± 0.13***
Values (means ± s.e.m. n = 7–8 animals per condition) are calculated for the
12-h dark phase after compound administration.
**P < 0.01 and ***P < 0.001 vs. Vehicle based on one-way ANOVA followed by
Dunnett’s multiple comparison post-hoc test.
NREM Bout Number [F(2,19) = 44.58, p < 0.001]; NREM Bout Duration [F(2,19) =
19.38, p < 0.001]; REM Bout Number [F(2,19) = 14.10, p < 0.001]; REM Bout
Duration [F(2,19) = 13.94, p < 0.001].
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FIGURE 2 | Representation of DREM in an animal after administration of the OX1/2R antagonist SB-649868. The arrows on the hypnogram represent
the respective DREM and REM episodes illustrated on corresponding EEG/EMG traces.
(10mg /kg) or the selective OX2R antagonist JNJ-10397049
(10mg/kg) alone, or in combination at the onset of the dark
phase. The results were presented in Figure 3 for the first 6-h
period after dosing, based on the shorter duration of both the
sleep-promoting effect of JNJ-10397049 and the sleep response
elicited by simultaneous injection of GSK-1059865 at the respec-
tive doses tested. Sleep-wake parameters were not affected during
the second 6-h period (data not shown). Administration of the
OX2R antagonist alone induced a significant reduction in NREM
sleep latency (Figure 3A) and an increase in NREM sleep dura-
tion (Figures 3C,D) relative to vehicle treatment.While the OX1R
antagonist had no effect on NREM sleep by itself, its admin-
istration significantly attenuated the NREM sleep prolongation
evoked by the OX2R antagonist (Figures 3C,D). Indeed, in the
combined treatment condition the NREM bout duration was
significantly reduced relative to all other conditions (Table 2),
accounting for the less pronounced increment in total NREM
sleep duration. The time course analysis shows that the reduced
effect on NREM sleep occurred 2 h after the additional admin-
istration of GSK-1059865 (Figure 3C), and consequently the
NREM sleep latency was not affected (Figure 3A). REM sleep
onset (Figure 3B) and REM sleep duration (Figures 3E,F) were
not altered by either OX1R or OX2R pharmacological block-
ade. In contrast, when receiving the combined treatment the
animals displayed a reduced REM sleep latency (Figure 3B) and
the time spent in REM sleep was significantly increased as com-
pared to treatment with vehicle, OX1R or OX2R antagonist alone
(Figures 3E,F). This REM sleep-promoting effect was observed
mainly during the first 4 h following the treatment (Figure 3E)
and was due to a significant prolongation of the REM bout
duration as well as a tendency to enhanced REM bout num-
bers (Table 2). Ultimately, the results showed that additional
pharmacological blockade of OX1R attenuated the NREM sleep-
promoting effects of an OX2R antagonist by increasing REM
sleep duration and concomitantly decreasing NREM sleep dura-
tion, leading to a significant enhancement of the REM/total
sleep ratio (% REM/TS) as illustrated in Figure 3G. Similarly, a
markedly elevated % REM/TS was found following the admin-
istration of the dual OX1/2R antagonist SB-649868 at the doses
of 10mg/kg (24.6%) and 30mg/kg (26.4%) as compared to
vehicle treatment (14.6%) over the 12-h dark phase. Therefore,
both experimental approaches produced a disinhibition of REM
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FIGURE 3 | Desinhibition of REM sleep in rats by additional
pharmacological blockade of OX1R to OX2R antagonism. NREM (A)
and REM (B) sleep latency, duration of NREM (C,D) and REM (E,F) sleep,
and % REM/TS (G) were determined for 6 h after the coadministration of
GSK-1059865 (10mg/kg) and JNJ-10397049 (10mg/kg) at dark onset.
Values (means ± s.e.m. n = 7 animals) are expressed in minutes (except
G). Statistical significance (∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001) was
based on repeated measures one-way ANOVA followed by Newman–Keuls
post-hoc test (A) [F(3, 6) = 17.87, p < 0.001], (B) [F(3, 6) = 3.72, p = 0.03],
(D) [F(3, 6) = 11.59, p < 0.001], (F) [F(3, 6) = 5.59, p = 0.006], and (G)
[F(3, 6) = 7.41, p = 0.002] or repeated measures two-way ANOVA
(interaction Time × Treatment) followed by Bonferroni post-hoc test (C)
[F(6,48), = 1.27, p = 0.288] and (E) [F(6, 48) = 2.78, p = 0.021].
sleep by shifting the balance in favor of REM sleep at the
expense of NREM sleep. However, unlike with SB-649868, no
DREM episodes were detected with the coadministration of GSK-
1059865 and JNJ-10397049.
DISCUSSION
The present investigation demonstrated that pharmacological
blockade of both OX1R and OX2R is effective in promoting both
NREM and REM sleep but produced an alteration of the sleep
stages distribution due to a striking impact on REM sleep. The
dual OX1/2R antagonist SB-649868 primarily reduced REM sleep
latency and prolonged REM sleep time in comparison to a less
Table 2 | NREM and REM bout analysis after co-administration of the
OX1R antagonist GSK-1059865 (10mg/kg) and the OX2R antagonist
JNJ-10397049 (10mg/kg) in rats.
NREM bout NREM bout REM bout REM bout
number duration (min) number duration (min)
Vehicle + Vehicle 82.7±2.6 1.39± 0.07 19.6± 2.0 1.13± 0.13
GSK-1059865 +
Vehicle
70.7±3.7*a 1.51± 0.10c 18.1± 1.7 1.21± 0.17
Vehicle +
JNJ-10397049
101.0±4.2** 1.30± 0.07 17.7± 3.6 1.37± 0.18
GSK-1059865 +
JNJ-10397049
97.9±3.0* 1.17± 0.07*,b 23.0± 2.1 1.55± 0.11**,b
Values (means ± s.e.m. n = 7 animals) are calculated for the 6-h period following
the treatment.
*P < 0.05 and **P < 0.01 vs. Vehicle + Vehicle
aP < 0.001 vs. Vehicle + JNJ-10397049 and GSK-1059865 + JNJ-10397049
bP < 0.01 vs. GSK-1059865 + Vehicle
cP < 0.05 vs. Vehicle + JNJ-10397049
As determined by repeated measures One-Way ANOVA followed by Newman–
Keuls post-hoc test.
NREM Bout Number [F(3, 6) = 13.69, p < 0.001]; NREM Bout Duration [F(3, 6) =
7.79, p = 0.001];
REM Bout Number [F(3, 6) = 1.28, p = 0.313]; REM Bout Duration [F(3, 6) = 6.76,
p = 0.003].
pronounced NREM sleep-promoting effect. Similarly, adminis-
tration of a selective OX1R antagonist in combination with a
selective OX2R antagonist exclusively enhanced REM sleep by
counteracting the NREM sleep-promoting effects evoked by the
OX2R blockade. Therefore, transient pharmacological inhibition
of the two receptors, either by a dual OX1/2R antagonist or by
simultaneous blockade of OX1R to OX2R antagonism, disrupted
sleep architecture by shifting the balance in favor of REM sleep at
the expense of NREM sleep.
Selective pharmacological blockade of OX2R by JNJ-10397049
promotes sleep by inhibiting the output of wake active neu-
rons, mainly by suppressing histamine release in the hypothala-
mus (Dugovic et al., 2009). Conversely, orexin-A administration
increased cortical histamine release without affecting the nore-
pinephrine or serotonin release in mice (Hong et al., 2005). The
robust hypnotic properties of several selective OX2R antagonists
after systemic administration in rats and mice have been con-
firmed by other groups (Gozzi et al., 2011; Morairty et al., 2012;
Betschart et al., 2013). In these dose-response studies, results
showed that NREM sleep was firstly increased at low dosage and
that REM sleep was progressively enhanced at higher doses, with
no obvious change in the REM/TS ratio indicating a preservation
of the sleep architecture. By contrast to selective OX2R antago-
nists, pharmacological (using various OX1R antagonists with dis-
tinct chemical structures) or genetic selective inhibition of OX1R
in rodent models has been reported to minimally affect sleep-
wake states in baseline conditions (Smith et al., 2003; Sakurai,
2007; Dugovic et al., 2009; Gozzi et al., 2011). Controversial data
has been reported in one study with the OX1R antagonist SB-
334867 (Morairty et al., 2012) which is less selective and less
potent thanGSK-1059865 and exhibits off target activities (Gotter
et al., 2012). Our results confirm the absence of sleep-promoting
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effects of GSK-1059865 previously reported by Gozzi et al. (2011),
and a more recent study showed that the new selective OX1R
antagonist ACT-335827 did not alter sleep in rats (Steiner et al.,
2013). However, due to the paucity of publically available selective
orexin compounds, SB-334867 remains so far the most studied
OX1R antagonist and has been found to reverse the arousal and
REM sleep suppression induced by pharmacological (orexin-A
injection) or optogenetic activation of orexin neurons through
OX1R in the locus coeruleus (Bourgin et al., 2000; Smith et al.,
2003; Carter et al., 2012).
Within the last decade, dual OX1/2R antagonists have been
developed as therapeutics for insomnia and their hypnotic prop-
erties have been demonstrated in animals, human volunteers, and
insomnia patients. The development of the former compounds
almorexant and SB-649868 has been stopped for undisclosed
adverse effects; suvorexant is in the latest stage of clinical devel-
opment and is followed by its back up compound filorexant
(Winrow and Renger, 2014). In the present study, rats treated
with SB-649868 at the onset of their active/dark phase displayed a
markedly reduced REM sleep latency and the first episode of REM
sleep was observed shortly after NREM sleep onset (Figure 1).
While both sleep stages were enhanced, the predominant increase
in REM sleep was reflected by the abnormally elevated REM/TS
ratio compared to vehicle treatment. These data are in agreement
with those previously found in rats when SB-649868 was dosed
in the middle of the dark phase (Di Fabio et al., 2011). A simi-
lar increase in the proportion of REM vs. NREM sleep has been
reported in mice dosed with almorexant or suvorexant (Mang
et al., 2012; Betschart et al., 2013; Black et al., 2013), although
not in rats (Brisbare-Roch et al., 2007; Winrow et al., 2011).
Our visual examination of EEG/EMG recordings revealed the
occurrence of at least one episode of REM intrusion into wake
(DREM) in 4 out of 7 animals dosed with SB-649868 (Figure 2).
Simultaneous video recordings were not performed, therefore the
behaviors associated with this activity during this unusual state
transition in these rats are unclear. However, we did not observe
any DREM event with the coadministration of the OX1R antago-
nist GSK-1059865 and the OX2R antagonist JNJ-10397049.While
both compounds exhibit efficient brain-penetrating properties
(see ex vivo receptor occupancy in methods), the REM sleep pro-
motion produced by SB-649868 was much more pronounced
and long-lasting as compared to the combined treatment, that
might increase the possibility to trigger DREM transitions. In
a murine model of narcolepsy, the orexin/ataxin-3 transgenic
mouse, almorexant exacerbated spontaneous cataplexy, and pos-
sibly elicited cataplexy-like events in some wild type mice after
wheel running activity (Black et al., 2013). In a preliminary
investigation conducted in mice deficient for the OX2R, we also
observed episodes of DREM following the treatment with another
dual OX1/2R antagonist (Dugovic et al., 2012). Mice lacking both
orexin receptors or the orexin peptide exhibit some cataplexy
spontaneously (Sakurai, 2007) that can be substantially increased
by pleasurable activity such as wheel running or eating highly
palatable foods (Espana et al., 2007; Clark et al., 2009; Oishi
et al., 2013). Cataplexy, a pathological intrusion of REM sleep
atonia into wakefulness, has not been reported with almorexant
or suvorexant in clinical or preclinical studies in situations where
cataplexy is not provoked (Brisbare-Roch et al., 2007; Winrow
and Renger, 2014). However, there are no disclosed clinical trials
with an OX1/2R antagonist under conditions of positive emo-
tional stimuli that are known to trigger cataplexy in narcolepsy
with cataplexy patients.
Narcoleptic patients also exhibit sleep onset REM (SOREM)
episodes usually defined as REM sleep latency shorter than 15min
(Nishino and Mignot, 1997). After SB-649868 administration,
SOREM episodes were observed in Phase I studies (Bettica et al.,
2012a), in a model of situational insomnia in healthy volunteers
(Bettica et al., 2012b), as well as in patients with primary insom-
nia (Bettica et al., 2012c). Although SOREM episodes were not
detected after administration of almorexant or suvorexant in pri-
mary insomnia patients, it is noteworthy that the latency for REM
sleep was significantly reduced at half the dose required to shorten
the latency to persistent sleep for both compounds (Herring et al.,
2012; Hoever et al., 2012). In patients with primary insomnia
treated with suvorexant or SB-649868, the increase in total sleep
time resulted from a higher percentage of time spent in REM
sleep and to a lesser degree in stage-2 sleep (Bettica et al., 2012c;
Herring et al., 2012). Therefore, the preferential sleep-promoting
action of dual OX1/2R antagonists on REM sleep relative to
NREM sleep in animal studies seems to be predictive of the
alterations in sleep architecture observed in humans.
The results of the experiment conducted in rats receiving the
selective OX1R antagonist GSK-1059865 and the selective OX2R
antagonist JNJ-10397049 in combination were consistent with
the data obtained with the dual OX1/2R antagonist SB-649868.
While REM sleep was not affected either by the OX2R antagonist
or the OX1R antagonist alone, their coadministration reduced
REM sleep latency and prolonged REM sleep time. Concurrently,
the magnitude of the NREM sleep promoting effect elicited by
the OX2R blockade was attenuated, demonstrating a shift in the
balance between NREM and REM sleep. In a previous investi-
gation carried out during the light/rest phase of the rat using
the same selective OX2R antagonist, but with the OX1R antag-
onist SB-408124 which displayed less brain penetration (Gotter
et al., 2012), we mainly observed a diminution in NREM sleep
with the combined treatment vs. the OX2R antagonism alone
(Dugovic et al., 2009). Together, these data indicate that addi-
tional OX1R blockade attenuated the NREM sleep promoting
effect of an OX2R antagonist by disinhibiting REM sleep likely
through OX1R.
In summary, we demonstrated that OX1R blockade dysreg-
ulates REM sleep in the presence of OX2R antagonism. These
findings reinforce the consensus based on various animal models
that wake to NREM sleep transitions depend on OX2R signal-
ing and that REM sleep dysregulation occurs by the loss of both
OX1R and OX2R function (Willie et al., 2003; Mieda et al., 2011;
Mochizuki et al., 2011), thereby confirming the distinct contri-
bution of OX1R and OX2R in the control of sleep-wake states.
Key insights recently gained from the above clinical studies sug-
gest that transient blockade of orexin receptors by dual OX1/2R
antagonists induce a preferential disinhibition of REM sleep rel-
ative to NREM sleep, and may cause a dysregulation of REM
sleep. Since the blockade of OX2R is sufficient to initiate and
promote sleep in animals, future clinical studies with selective
Frontiers in Neuroscience | Neuropharmacology February 2014 | Volume 8 | Article 28 | 6
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OX2R antagonists should answer the question of whether this
hypothesis is translatable to humans.
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